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Side Population Cells from Human Melanoma Tumors
Reveal Diverse Mechanisms for Chemoresistance
Yuchun Luo1, Lixia Z. Ellis1, Katiuscia Dallaglio1,2, Moe Takeda1, William A. Robinson3,
Steven E. Robinson3, Weimin Liu1, Karl D. Lewis3, Martin D. McCarter4, Rene Gonzalez3,
David A. Norris1,5, Dennis R. Roop1,2, Richard A. Spritz6, Natalie G. Ahn7 and Mayumi Fujita1,2,5
Side population (SP) cells are identified as cells capable of excluding the fluorescent Hoechst dye and
anticancer drugs, and it represents hematopoietic stem cells and chemoresistant cells from several solid
tumors. In this study, we confirmed the presence of SP cells in tumors from melanoma patients. Melanoma SP
cells overexpressed ATP-binding-cassette (ABC) transporters, ABCB1 and ABCB5. We generated a direct in vivo
xenograft model, and demonstrated that SP cells were resistant to paclitaxel, a substrate of ABCB1, both in vitro
and in vivo. However, melanoma SP cells were also resistant to temozolomide, which is not a substrate for ABC
transporters, through IL-8 upregulation. In addition, gene profiling studies identified three signaling pathways
(NF-kB, a6-b4-integrin, and IL-1) as differentially upregulated in melanoma SP cells, and there was a significant
increase of PCDHB11 and decrease of FUK and TBX2 in these cells. Therefore, we provide evidence that SP is an
enriched source of chemoresistant cells in human melanomas, and suggest that the selected genes and
signaling pathways of SP cells may be a potential target for effective melanoma therapies. To our knowledge,
this is a previously unreported study to isolate SP cells from melanoma patients and to investigate the gene
expression profiling of these cells.
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INTRODUCTION
Malignant melanoma is the fifth most common cancer in the
United States (Siegel et al., 2011) and the deadliest form of
skin cancer. Despite various types of treatments, advanced
stages of melanoma cells have proven to be intrinsically
resistant to many therapies. Multiple mechanisms contribute
to the development of drug resistance in melanoma,
including induction of enzyme systems, reduced apoptosis,
increased DNA repair, and intra- and extra-cellular drug
transport (Helmbach et al., 2001; La Porta, 2007).
One of the well-known mechanisms of chemoresistance
in cancers is the enhanced efflux of a broad spectrum of
hydrophobic cytotoxic drugs. Recently, the ability to exclude
the fluorescent Hoechst 33342 dye has been employed to
isolate a side population (SP) from hematopoietic cells (Goodell
et al., 1996). This phenotype of low fluorescent staining pattern
results from a family of transporter proteins known as ATP-
binding cassette (ABC) transporters, which are responsible for
the exclusion of Hoechst 33342 (Helmbach et al., 2001;
Gottesman et al., 2002). These SP cells have stem cell–like
properties and are capable of self-renewal and differentiation
(Dean et al., 2005). These characteristics of SP cells have also
been found in various types of tumors (Hirschmann-Jax et al.,
2004; Grichnik et al., 2006; Dean, 2009; Dou et al., 2009;
Zhong et al., 2010), and SP cells with a high drug efflux
capacity are identified as the potential cause of the chemo-
resistant phenotypes of cancer stem cells in human tumors
(Hirschmann-Jax et al., 2004; Dean et al., 2005).
SP cells have previously been isolated from human
melanoma cell lines (Grichnik et al., 2006), but are yet to
be isolated directly from patient melanoma tumors. One
major challenge of analyzing patient samples is that
substantial quantities of fresh tumor tissues are not available
for isolation and investigation of SP cells that comprise only
a small percentage of the tumor cells. Another difficulty is
that experiments to further characterize biology and function
of these cells are limited by the technical difficulties in
preserving and expanding tumor cells that faithfully repre-
sent patient tumor biology. To that end, a direct in vivo
xenograft model provides cohorts of tumor-bearing mice
suitable for further biological analyses and drug treatment
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(Rubio-Viqueira et al., 2006). Maintaining tumor xenografts
exclusively in vivo retains fundamental genotypic features of
the primary tumor of direct relevance to preclinical drug
testing (Rubio-Viqueira et al., 2006; Daniel et al., 2009).
Therefore, to isolate and characterize the molecular features
of a small fraction of SP cells in patient melanoma samples,
we generated a direct in vivo xenograft model from human
melanoma tumors. Furthermore, our gene profiling analysis
discovered a series of genes and pathways potentially
involved in chemoresistance in melanoma SP cells.
RESULTS
Patient melanoma tumors contain SP that excludes Hoechst dye
The presence of SP cells in patient melanoma tissues was first
investigated by staining single-cell suspensions with Hoechst
33342 dye. Flow cytometry plots depict Hoechst excitation
at blue and red wavelengths. The cells with the least amount
of Hoechst staining, which disappear in the presence of
verapamil, an inhibitor of Hoechst 33342 transport, are gated
as SP (Figure 1a). All of the patient melanoma tumors,
including three skin primary melanomas and five metastatic
melanomas, contained a small but clear SP fraction, ranging
from 0.13 to 0.7% of all gated cells (Figure 1b). We then
generated a direct in vivo xenograft model from human
melanoma specimens to characterize SP cells from patient-
derived tumors (Figure 1c). Original patient tumors were
designated as F0 tumors, whereas those grown from F0
tumors were designated as F1 tumors. F1 tumors were further
implanted in F2 mice for in vivo drug treatment (Figure 1c).
After characterizing SP cells using this model, cells from
HS294T were utilized for further biological and mechanistic
studies because the cell line contains a larger SP fraction
(Supplementary Figure S1 online).
Melanoma SP cells are resistant to paclitaxel and temozolomide
in vitro and in vivo
SP cells expressing ABC transporters have been shown to be
resistant to multiple drugs (Duan et al., 2004; Dean, 2009).
Paclitaxel, a substrate of ABCB1 transporter (Duan et al.,
2004), has been widely evaluated and shown to have positive
outcomes in phase II/III clinical trials of malignant melanoma
(Bedikian et al., 2004; Hauschild et al., 2009). Therefore, we
treated human melanomas with paclitaxel to examine the
drug sensitivity of SP cells. Temozolomide, an alkylating
agent for melanoma treatment (Bleehen et al., 1995), is not a
substrate of ABC transporters and thus was used as a control.
As shown in Figure 2a, melanoma cells from MB1009-F1
tumor were sensitive to 20 nM paclitaxel treatment in vitro.
This treatment resulted in a 32.5-fold increase in SP cells
compared with vehicle control (Figure 2b). On the other
hand, temozolomide treatment induced less cell death, and
induced moderate increase in SP cells. The increase in SP
cells after drug treatment despite the absence of overall cell
increase indicates that SP cells are more resistant to the drugs
than non-SP cells.
To further analyze drug resistance in vivo, mice with
MB1009-F2 tumors were treated with paclitaxel or temozo-
lomide. Following paclitaxel treatment, a significant decrease
in tumor size (79.4±5.9% of original size) was observed
after 7 days, but the tumors grew thereafter (125.1±13.2% of
original size on day 14; Figure 2c). Temozolomide showed
inhibitory effects similar to paclitaxel in vivo. Tumor analysis
on day 14 revealed an increase in SP cells after paclitaxel
treatment and a modest increase after temozolomide treat-
ment when compared with vehicle (Figure 2d), indicating
that SP cells are resistant to paclitaxel and temozolomide
in vivo.
This relative resistance of SP cells to drugs was further
investigated by treating SP and non-SP cells with drugs
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Figure 1. Side population (SP) is a rare population in patient melanoma
tissues. (a) A representative SP flow cytometry profile from a patient tumor
tissue (MB952-F0). Cells were stained with Hoechst 33342 dye in the
presence (left panel) or absence (right panel) of verapamil. SP cells are shown
in the lower left gated area. (b) Frequency of SP fractions in eight patient
melanoma specimens (F0 tumors) and selected F1 tumors. (c) Study schema.
Clinical melanoma specimens (F0) were used for SP analysis and copy
number analysis. Tumor specimens used in each analysis are listed in
parentheses. Tumors were serially passaged into mice (F1, F2,- - -, Fn) for
further analyses. NA, not analyzed.
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separately. When SP cells and non-SP cells from HS294T
were treated with paclitaxel or temozolomide, SP cells
showed less sensitivity to both drugs than non-SP cells,
confirming the drug resistance of SP cells compared with
non-SP cells (Figure 2e).
ABCB1 and ABCB5 are selectively upregulated in human
melanoma SP cells
ABC transporters, particularly ABCB1 and ABCG2, have been
associated with resistance to multiple drugs (Dean et al.,
2001; Duan et al., 2004; Frank et al., 2005; Dean, 2009). To
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Figure 2. Drug resistance of side population (SP) cells. (a, left panels) Microscopic images of MB1009-F1 cells following 48-hour treatment with vehicle,
paclitaxel, or temozolomide in vitro. Bar¼100 mm. (a, right panel) Average number of cells in each microscopic field (n¼ 6). (b, left panels) SP cells from
MB952-F1 tumors after in vitro treatment. (b, right panel) Percentage of SP cells (n¼ 3). (c) Growth curve of MB1009-F2 tumors after treatment with vehicle,
paclitaxel, or temozolomide in vivo (n¼ 6). ***Po0.001 compared with vehicle. (d, left panels) SP cells from MB952-F2 tumors after in vivo treatment. (d, right
panel) Percentage of SP cells (n¼ 3). (e) Viability of SP and non-SP cells from HS294T after 72 hours of treatment with vehicle, paclitaxel, or temozolomide
(n¼3). All data represent mean±SE. *Po0.05, **Po0.01, ***Po0.001.
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identify the ABC transporters responsible for the exclusion of
Hoechst 33342 in melanoma SP cells, we first compared the
expression levels of all 48 ABC transporters between SP and
non-SP cells (from MB952-F1 and MB1009-F1 tumors) via
microarray analysis. Results demonstrated that SP cells
expressed 13-fold more ABCB1 and ABCB5 than non-SP
cells (Figure 3a), verifying the accuracy of the SP isolation
method and suggesting that these ABC transporters, but not
ABCG2, are likely responsible for the exclusion of Hoechst
33342. Upregulation of ABCB1 and ABCB5 in SP cells was
confirmed by real-time quantitative reverse transcription–PCR
(qRT-PCR) using MF347-F1 and MB1009-F1 tumors (Figure
3b), and flow cytometric analysis using HS294T (Figure 3c).
Resistance to paclitaxel in SP cells is associated with ABC
transporters
Because of the upregulation of ABCB1 and ABCB5 in SP cells,
we hypothesized that the drug resistance is associated with
these transporters. Consistent with the hypothesis, the expres-
sion of ABCB1 and ABCB5 was upregulated after treatment
with paclitaxel or temozolomide in vitro (in HS294T; Figure
4a) and in vivo (in MB1009-F2 tumors; Figure 4b).
In order to determine if drug resistance is associated
with a drug efflux capacity, tumor cells from MB952-F1
were treated with paclitaxel or temozolomide in vitro in
the presence or absence of verapamil, an efflux pump
inhibitor (Figure 4c). Verapamil treatment decreased sensi-
tivity to paclitaxel but not temozolomide, suggesting that
the resistance to paclitaxel in SP cells is at least partially
dependent on drug efflux.
Next, to determine if the drug resistance of SP cells is
associated with drug efflux by ABC transporters, we knocked
down ABCB1 and ABCB5 using small interfering RNA
(siRNA). Successful transfection of siRNA was confirmed by
reduction in mRNA at 18 hours (60% and 65% reduction of
ABCB1 and ABCB5, respectively) and protein levels at
72 hours in HS294T cells (Figure 4d). Compared with control
siRNA, transfection of ABCB1 and ABCB5 siRNAs led to 74%
and 62% reduction in SP percentage at 72 hours, respectively
(Figure 4e), suggesting that SP phenotype of melanoma cells
is associated with ABCB1 and ABCB5. Cell viability assay
revealed that transient transfection of ABCB1 and ABCB5
siRNAs in HS294T decreased sensitivity to paclitaxel (38%
and 39% decrease with ABCB1 and ABCB5 siRNAs,
respectively) but not temozolomide (Figure 4f), suggesting
that the resistance to paclitaxel in SP cells is dependent on
ABCB1 and ABCB5, whereas other mechanisms are respon-
sible for temozolomide resistance in these cells.
Resistance to temozolomide in SP cells is at least partly due to
IL-8 upregulation
Previous studies by other researchers have shown that IL-8,
sphingosine kinase (SPHK), mutL homolog (MLH), mutS
homolog (MSH), postmeiotic segregation (PMS), O-6-methyl-
guanine-DNA methyltransferase (MGMT), and excision
repair cross-complementing rodent repair deficiency, com-
plementation group (ERCC) 1 were related to the resistance to
temozolomide (Gerson, 2002; Narayan and Roy, 2003;
Chelouche-Lev et al., 2004; Pilorget et al., 2007; Boeckmann
et al., 2009). The expression levels of these genes in SP and
non-SP cells were therefore compared in our microarray data
using patient-derived tumors, and we found that IL-8, SPHK1,
and MLH3 were indeed selectively expressed in SP cells
(Figure 5a). As IL-8 was the most differentially expressed gene
(22-fold in MB952-F1 and 55-fold in MB1009-F1), we
focused on this molecule in our study. The upregulation of
IL-8 in SP cells was verified by qRT-PCR in melanoma tissues
(3.8-fold and 23.2-fold in MB952-F1 and MB1009-F1 tumors,
respectively; Figure 5b) and HS294T (2.8-fold; Figure 5c).
This was further confirmed by ELISA analysis in melanoma
tumor cells (16.1-fold in MB952-F1; Figure 5b) and HS294T
(5.2-fold; Figure 5c). When HS294T cells were treated with
paclitaxel or temozolomide, IL-8 expression was enhanced
2.7-fold or 2.2-fold, respectively (Figure 5d). To determine
whether this increased IL-8 expression plays a role in
temozolomide resistance, we blocked the IL-8 signaling
pathway using anti-CXCR1, a neutralizing antibody for IL-8R,
in HS294T cells, and found this blockade significantly
increased the sensitivity of SP cells to temozolomide, an
effect not observed in non-SP cells (Figure 5e). We then
knocked down IL-8 using siRNA. Successful transfection of
siRNA was confirmed by reduction in mRNA at 18 hours
(69%) and secreted cytokine level at 72 hours (37%) in
HS294T cells (Figure 5f). Compared with control siRNA,
transfection of IL-8 led to a 48% reduction of SP percentage
at 72 hours (Figure 5g), suggesting that SP phenotype of
melanoma cells is associated with IL-8. Furthermore, cell
viability assay revealed that transient transfection of IL-8
siRNA in HS294T decreased sensitivity to temozolomide
(42%) but not paclitaxel (Figure 5h), suggesting that the
resistance to temozolomide in SP cells is at least partially
dependent on IL-8.
Because ABCB1, ABCB5, and IL-8 are associated with SP
phenotypes, we investigated if they are related to each other.
We found that transfection of IL-8 siRNA did not affect
the expression levels of ABCB1 and ABCB5 at 18 hours
(Supplementary Figure S2a online), and that transfection of
ABCB1 or ABCB5 siRNA did not affect IL-8 expression levels
at 18 hours either (Supplementary Figure S2b), suggesting that
these two mechanisms (ABC transporters and IL-8) are not
directly associated with each other.
Gene profiling analyses via microarray and qRT-PCR
To further delineate chemoresistant mechanisms, we con-
ducted microarray analysis to compare differentially ex-
pressed genes between SP and non-SP cells. A total of 1,729
transcripts were upregulated and 1,888 transcripts were
downregulated in SP cells (Po0.05, fold change 42.0;
Supplementary Figure S3a online). The most common
biological processes of these transcripts defined by gene
ontology annotations included cellular process (28.54%),
metabolic process (17.51%), and biological regulation
(17.38%; Supplementary Figure S3b online). Significant
pathway analysis using the 3,617 differentially expressed
transcripts identified NF-kB, a6-b4-integrin, and IL-1 path-
ways (Po0.05; Supplementary Figure S4 online).
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More stringent analysis (Po0.001 and fold change 415)
revealed three unregulated genes (AXL, PCDHB11, and
ZNF519) and six downregulated genes (TBX2, FUK, IL1R1,
RAB40C, ACE, and UTF1) in SP cells (Figure 6a). Because of
the limited amount of SP complementary DNA template, only
one unregulated gene (PCDHB11) and two downregulated
genes (TBX2 and FUK) were validated by qRT-PCR. Expres-
sion of PCDHB11 in SP cells from the MB1009-F1 tumor was
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0.073-fold relative to that of glyceraldehyde-3-phosphate
dehydrogenase but its expression in non-SP cell was below
the detection level (o1 107–fold; Figure 6b). Also, the
non-SP/SP ratio was 91.7-fold for FUK, as measured by qRT-
PCR, and 16.0-fold for TBX2. These results were further
confirmed using the MB952-F1 tumor.
Previous studies using a direct in vivo xenograft model of
pancreatic cancer have shown that the status of key genes in
pancreatic cancer is stable and drug susceptibility is a stable
trait after passaging tumors into mice (Rubio-Viqueira et al.,
2006). To address whether passaging melanoma tumors in
mice alters genes in this study, we determined the copy
number of six genes (ABCB1, ABCB5, IL8, PCDHB11, FUK,
and TBX2) in F0, F1, F2, and Fn tumors from two patient-
derived samples. As shown in Figure 6c, we observed high
concordance of gene copy number between original tumors
and xenografted tumors.
DISCUSSION
This study isolated SP cells not only from the original patient
melanoma tissues but also from in vivo xenograft mouse
models. Melanoma SP cells were shown to be resistant
to two melanoma drugs, paclitaxel and temozolomide, both
in vitro and in vivo. Melanoma SP cells overexpressed
ABCB1 and ABCB5, and their resistance to paclitaxel
was at least partly attributed to ABC transporters. Further-
more, IL-8 plays a role in chemoresistance to temozolomide
in SP cells. Microarray and qRT-PCR studies demonstrated
upregulation of PCDHB11 and downregulation of FUK and
TBX2 in SP cells, and identified NF-kB, a6-b4-integrin, and
IL-1 signaling networks differentially expressed between SP
and non-SP cells.
ABCB1, previously known as MDR1 or P-glycoprotein,
has been demonstrated to confer resistance to multiple
hydrophobic drugs (Gottesman et al., 2002). Primary cultures
of human melanoma contain ABCB1-positive cells that
coexpress ABCB5 and ABCC2 (Keshet et al., 2008). ABCB5
was recently shown to mediate chemoresistance in human
melanoma (Frank et al., 2005) and identify melanoma-
initiating cells (Schatton et al., 2008). ABCB1, ABCB4, and
ABCB5 are closely homologous (Tusnady et al., 2006), and
ABCB5 and ABCB1 have overlapping substrate specificities
(Frank et al., 2005), implying their cooperative functions in
mediating multidrug resistance in SP cells. Furthermore,
recent studies indicate that in addition to serving as drug
efflux pumps, ABC transporters also play fundamental roles in
melanogenesis (Chen et al., 2009), tumor biology (Fletcher
et al., 2010), and immunomodulation (Schatton et al., 2010).
Our results are consistent with the role that ABC transporters
play in melanomas and the chemoresistance signature that
characterizes SP cells.
The resistance of SP cells to temozolomide was observed
in a glioma study (Bleau et al., 2009), but the specific
mechanisms were not previously studied. Interestingly, we
found that IL-8 was upregulated in melanoma SP cells, which
is consistent with data from ovarian cancer and endometrial
SP cells (Moserle et al., 2008; Cervello et al., 2010). In
addition, we found that IL-8 upregulation is responsible for
chemoresistance to temozolomide in SP cells. IL-8 signaling
activates a set of cell survival and proliferation pathways
including MAPK, PI3-K, JAK2-STAT3, and b-catenin signaling
(Waugh and Wilson, 2008); thus, it comes as no surprise that
this molecule plays an important role in the intrinsic
chemoresistance of SP cells.
In addition to ABC transporters and IL-8, melanoma
SP cells expressed genes and pathways associated with
development, stemness, and metabolic process. For example,
PCDHB11 belongs to the protocadherin family, and
the lack of protocadherins causes massive apoptosis of
spinal interneurons in a mouse model (Lefebvre et al.,
2008). TBX2 is necessary for cell proliferation and suppres-
sion of senescence in melanoma (Vance et al., 2005). FUK is
associated with fucosylation, and reduced fucosylation in
cancer induces immunoevasion and metastasis (Moriwaki
et al., 2009).
Three pathways identified in melanoma SP cells
may be closely related to chemoresistance. For example,
NF-kB protects cells from apoptosis following DNA damage,
and is a principal mechanism for chemoresistance (Yama-
moto and Gaynor, 2001). Notably, NF-kB was shown
to induce ABCB1 expression (Zhou and Kuo, 1997;
Bentires-Alj et al., 2003). In addition, both a6-b4-integrin
and IL-1 signaling pathways induce resistance to apoptosis
by activation of NF-kB in tumors (Arlt et al., 2002; Weaver
et al., 2002).
Therefore, it appears that chemoresistance of SP cells
derives from at least two different types of mechanisms
(Figure 6d). One is the ABC-transporter-conferred resistance
due to the efflux of drugs. The other is the intrinsic resistance
to cytotoxic drugs, possibly by induction of certain signaling
pathways and enzyme systems, changes in cytoskeleton,
reduced apoptosis, and increased DNA repair.
In conclusion, we provide evidence that SP is an enriched
source of chemoresistant cells in human melanoma tumors.
These data will pave the road for further mechanistic studies
of melanoma SP cells, and provide potential targets for future
melanoma therapies.
MATERIALS AND METHODS
Clinical melanoma specimens
Human melanoma tissues were obtained from surgical specimens
with written patient consent under institutional review board-
approved protocols at the University of Colorado Hospital, adhering
to the Declaration of Helsinki Principles. Human melanoma tissues
were cut into 3-mm3 pieces, and processed for cell isolation and
direct in vivo xenograft.
Direct in vivo xenograft
Animal experiments were performed under the institutional guide-
lines for the use of laboratory animals. Under isofluorane anesthesia,
patient tumors were implanted into 6-week-old female athymic (nu/
nu) mice (NCI, Bethesda, MD) by a small incision and subcutaneous
pocket made in each side of the lower back (Rubio-Viqueira et al.,
2006). These mice were designated as F1 mice. F1 tumors were
harvested when reaching a size of 1,500mm3 and implanted into F2
mice. Tumors were serially passaged into mice.
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Tumor cell isolation and sorting of SP cells from tumor cells
Mechanically minced tumor tissues were digested with 235Uml1
collagenase (Sigma-Aldrich, St Louis, MO) and 850Uml1 hyalur-
onidase (Sigma-Aldrich) for 2 hours at 37 1C with intermittent vortex,
followed by sequentially passing through 70- and 40-mm filters to
obtain single-cell suspension. Red blood cells were lysed using 1
Red Blood Cell Lysis Buffer (eBioscience, San Diego, CA). Cells were
washed and re-suspended in DMEM with 2% fetal bovine serum and
1% HEPES at a concentration of 1 106 cells per ml, and stained
with Hoechst 33342 dye (5mgml1, Sigma-Aldrich) in the presence
or absence of Verapamil (50 mM, Sigma-Aldrich) at 37 1C for
90minutes with intermittent vortex. Propidium iodide (1 mgml1)
was used to remove dead cells. Human stromal cells were
eliminated from human melanoma tumors using phycoerythrin-
cy7-labeled anti-human CD45 (eBioscience) and anti-human CD31
(eBioscience) antibodies. Mouse stromal cells were eliminated
from xenografted tumors using phycoerythrin-cy7-labeled anti-
mouse CD45 (eBioscience) and anti-mouse CD31 (eBioscience)
antibodies. Human melanoma cells were then positively selected
by allophycocyanin-labeled anti-human CD147 (eBioscience).
SP and non-SP cells were sorted by MoFlo (DakoCytomation,
Carpinteria, CA) and the results were analyzed with Summit software
(DakoCytomation).
Sorting of SP cells from cell lines
Human metastatic melanoma cell line, HS294T, was obtained from
the American Type Culture Collection (Manassas, VA). Cells were
maintained in RPMI-1640 medium (Mediatech, Manassas, VA)
supplemented with 10% fetal bovine serum (Mediatech), 100 units
per ml penicillin, 0.1mgml1 streptomycin, and 2mM L-glutamine.
Single cells were prepared using 1mM EDTA (Sigma-Aldrich) for
15minutes at 37 1C and stained with Hoechst 33342 dye for SP analysis
and sorting. Single cells were also used for biological analysis.
Copy number analysis of melanoma cells
DNA from human melanoma cells was isolated using QIAamp DNA
Mini Kit (Qiagen, Valencia, CA) and quantified by PicoGreen
dsDNA assay (Invitrogen, Grand Island, NY). Melanoma DNA
(250 ng) was hybridized to SNP probes (Illumina, San Diego, CA) at
the University of Colorado Denver microarray core. Probes consisted
of 595 markers: 293 for ABCB1 (chr7:87132948-87342611); 249 for
ABCB5 (chr7:20654830-20816658); 6 for IL-8 (chr4:74606223-
74609433); 6 for PCDHB11 (chr5:140579183-140582618); 31 for
FUK (chr16:70488498-70514177); and 10 for TBX2 (chr17:
59477257-59486827). Probe copy number was analyzed using
CNApartition V3.1.6 (Illumina).
Other methods
Further information about the materials and methods used in this
work are provided in the Supplementary Materials and Methods
online section.
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